ArticleNature medicine2023
Senolytic therapy in mild Alzheimer's disease: a phase 1 feasibility trial.
Open access · greenAbstract readClinical Trial, Phase I
In one paragraph
Article in Nature medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 174 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
174citing papers in PubMed, 1 pooled it
38.2field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
174 citing papers in PubMed, 1 synthesis or guideline pooled it, 218 citations in OpenAlex.
- The intellectual landscape of cognitive impairment in type 2 diabetes: knowledge structure, research focuses and rising trends.Frontiers in endocrinology · 2026Pooled it
- Exploratory Effects of a Novel Nutraceutical on Senescence-Related Protein Biomarkers in Healthy Adults: A Pilot Proteomics Study.International journal of molecular sciences · 2026Trial
- Quercetin Reduces Vascular Senescence and Inflammation in Symptomatic Male but Not Female Coronary Artery Disease Patients.Aging cell · 2025Trial
- Biomarkers of cellular senescence predict risk of mild cognitive impairment: Results from the lifestyle interventions for elders (LIFE) study.The journal of nutrition, health & aging · 2025Trial
- Effects of intermittent senolytic therapy on bone metabolism in postmenopausal women: a phase 2 randomized controlled trial.Nature medicine · 2024Trial
- A randomized placebo-controlled trial of nicotinamide riboside in older adults with mild cognitive impairment.GeroScience · 2024Trial
- Overcoming the blood‒brain barrier: nanomedicine strategies for targeted delivery and multimodal therapy in Alzheimer's disease.Drug delivery · 2026Review
- Oxidative stress biomarkers and flavonoids in Alzheimer's disease: current clinical evidence and therapeutic perspectives.Redox report : communications in free radical research · 2026Review
- Prophylactic quercetin administration attenuates pulmonary fibrosis via ferroptosis-resistant priming of alveolar epithelial cells.Redox report : communications in free radical research · 2026Article
- Harnessing the NKG2D immune surveillance pathway using engineered T-cells for the treatment of human disease.Human vaccines & immunotherapeutics · 2026Review
- Mitochondrial dysfunction and inflammaging: a mechanistic bridge between bioenergetic failure and senescence.GeroScience · 2026Review
- Cellular senescence: six decades of discovery and reinvention.The EMBO journal · 2026Review
- A compendium of circulating biomarkers of senescence in humans: Insights on mechanistic impact across health domains and modulation by therapeutic interventions.Ageing research reviews · 2026Review
- Senolytics dasatinib and quercetin in metabolic dysfunction-associated steatohepatitis: a proof-of-principle randomized, controlled trial.Nature metabolism · 2026Article
- Lipophagy and lipid droplets in neurodegeneration.Trends in pharmacological sciences · 2026Review
- Chronic subdural hematoma through the hallmarks of aging: a geroscience framework for the commonest neurosurgical condition of older adults.GeroScience · 2026Review
- Tyrosine kinase inhibitor use and risk of neurodegenerative disease: A Swedish population-based cohort study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Targeting innovative therapeutic approaches to the hallmarks of aging to combat Alzheimer's disease.Neural regeneration research · 2026Article
- The role of senescence in kidney ageing, injury and fibrosis.Nature reviews. Nephrology · 2026Review
- Review
114 more citing papers are in PubMed but not listed here.
Corrections and comments
- Update of
Authors and funding
20 authors at 7 institutions in 1 country.
Mitzi M GonzalesGlenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA. gonzalesm20@uthscsa.edu.
Valentina R GarbarinoGlenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.ORCID 0000-0002-0973-7186
Tiffany F KautzGlenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
Juan Pablo PalaviciniDepartment of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.ORCID 0000-0001-9667-8438
Marisa Lopez-CruzanDepartment of Psychiatry & Behavioral Sciences, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.ORCID 0000-0003-0285-1012
Shiva Kazempour DehkordiGlenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.ORCID 0000-0003-0349-4360
Julia J MathewsGlenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
Habil ZareGlenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.ORCID 0000-0001-5902-6238
Peng XuDepartment of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York City, NY, USA.ORCID 0000-0001-8007-9879
Bin ZhangDepartment of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York City, NY, USA.
Crystal FranklinResearch Imaging Institute, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
Mohamad HabesGlenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
Suzanne CraftDepartment of Internal Medicine Section on Gerontology and Geriatric Medicine, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
Ronald C PetersenDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0002-8178-6601
Tamara TchkoniaDepartment of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0003-4623-7145
James L KirklandDepartment of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0003-1676-4905
Arash SalardiniGlenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
Sudha SeshadriGlenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
Nicolas MusiDepartment of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Miranda E OrrDepartment of Internal Medicine Section on Gerontology and Geriatric Medicine, Wake Forest University School of Medicine, Winston-Salem, NC, USA. morr@wakehealth.edu.ORCID 0000-0002-0418-2724
The University of Texas Health Science Center at San Antonio · USIcahn School of Medicine at Mount Sinai · USMayo Clinic in Arizona · USWake Forest University · USBoston University · USCedars-Sinai Medical Center · USMayo Clinic in Florida · US
Funding
Project 1U19AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI MICHAEL W WEINER · 2016 to 2026
$226.7MThe Alzheimer's Clinical Trial Consortium - Down Syndrome Network (ACTC- DSN)U24AG057437 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Paul S. Aisen, RONALD C PETERSEN · 2018 to 2026
$198.4MDISCOVERY - Statistics and Analysis CoreU19NS115388 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI Steven M Greenberg, Natalia S Rost · 2019 to 2026
$75.4MSUPPLEMENT TO ALZHEIMERS DISEASE PATIENT REGISTRYU01AG006786 · NIA · MAYO CLINIC ROCHESTER · PI GRAFF-RADFORD, JONATHAN, JACK, CLIFFORD R. · 1986 to 2023
$49.6MResearch Education ComponentP30AG062677 · NIA · MAYO CLINIC ROCHESTER · PI Walter K. Kremers · 2019 to 2026
$33.5MTRANSGENIC COREP30AG013319 · NIA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI PETER J HORNSBY · 1995 to 2026
$30.6MTargeting Cellular Senescence to Extend HealthspanP01AG062413 · NIA · MAYO CLINIC ROCHESTER · PI Joao Passos · 2019 to 2026
$28.7MCenter for Testing Potential Anti-Aging InterventionsU01AG022307 · NIA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI RANDY STRONG, Adam Salmon · 2004 to 2026
$26.3MIntegrative Network Biology Approaches to Identify, Characterize and Validate Molecular Subtypes in Alzheimer's DiseaseU01AG046170 · NIA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI WANG, MINGHUI, ZHANG, BIN · 2013 to 2022
$26.0MWake Forest University School of Medicine Alzheimer's Disease Research CenterP30AG072947 · NIA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI SUZANNE CRAFT · 2021 to 2026
$24.3MSouth Texas Alzheimer's Disease Research CenterP30AG066546 · NIA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Sudha Seshadri · 2021 to 2026
$24.0MPRECURSORS OF STROKE INCIDENCE AND PROGNOSISR01NS017950 · NINDS · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Hugo Javier Aparicio, Jose Rafael Romero · 1985 to 2026
$22.9MAlzheimer's Association PTC REG-20-651687BLRD VA I01 BX005717NCATS NIH HHS TL1 TR002647NHLBI NIH HHS R01 HL105756NIA NIH HHS P01 AG062413NIA NIH HHS P30 AG013319NIA NIH HHS P30 AG044271NIA NIH HHS P30 AG062677NIA NIH HHS P30 AG066546NIA NIH HHS P30 AG072947NIA NIH HHS R01 AG013925NIA NIH HHS R01 AG033193NIA NIH HHS R01 AG054076NIA NIH HHS R01 AG057896NIA NIH HHS R01 AG065301NIA NIH HHS R01 AG066524NIA NIH HHS R01 AG068030NIA NIH HHS R01 AG068293NIA NIH HHS R01 AG069690NIA NIH HHS R01 AG075684NIA NIH HHS R01 AG077472NIA NIH HHS R01 AG080821NIA NIH HHS R33 AG061456NIA NIH HHS R37 AG013925NIA NIH HHS RF1 AG059421NIA NIH HHS RF1 AG063507NIA NIH HHS RF1 AG065301NIA NIH HHS T32 AG021890NIA NIH HHS U01 AG006786NIA NIH HHS U01 AG022307NIA NIH HHS U01 AG046170NIA NIH HHS U19 AG024904NIA NIH HHS U24 AG057437NIA NIH HHS U24 AG059624NINDS NIH HHS R01 NS017950NINDS NIH HHS R21 NS125171NINDS NIH HHS RF1 NS112391NINDS NIH HHS U19 NS115388NINDS NIH HHS UF1 NS125417
Abstract
Cellular senescence contributes to Alzheimer's disease (AD) pathogenesis. An open-label, proof-of-concept, phase I clinical trial of orally delivered senolytic therapy, dasatinib (D) and quercetin (Q), was conducted in early-stage symptomatic patients with AD to assess central nervous system (CNS) penetrance, safety, feasibility and efficacy. Five participants (mean age = 76 + 5 years; 40% female) completed the 12-week pilot study. D and Q levels in blood increased in all participants (12.7-73.5 ng ml
Indexed as
Alzheimer DiseaseAgedAged, 80 and overAmyloid beta-PeptidesBiomarkersDasatinibFeasibility StudiesFemaleHumansMalePilot ProjectsSenotherapeuticsAmyloid beta-PeptidesBiomarkersDasatinibSenotherapeutics
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.